Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 9, 2006, Pages 1388-1393

  Shirin, Haim ^a,d   Moss, Steven F ^b   Kancherla, Sandy ^c   Kancherla, Kevin ^c   Holt, Peter R ^c   Weinstein, I Bernard ^c   Sordillo, Emilia M ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b BROWN UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Cyclooxygenase 2; Helicobacter pylori; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; COTRIMOXAZOLE; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; SALICYLATE SODIUM; SALICYLIC ACID DERIVATIVE; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; ENZYME INHIBITION; ESCHERICHIA COLI; GASTROINTESTINAL MUCOSA; GROWTH INHIBITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SHIGELLA BOYDII; STAPHYLOCOCCUS AUREUS; STOMACH CANCER;

EID: 33746644529     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04194.x     Document Type: Article

References (39)

1. Bourke B, Jones NL. Pathogenesis of Helicobacter pylori infection. Curr. Opin. Gastroenterol. 2001; 17: 24-29.
2. Fu S, Ramanujam KS, Wong A et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999; 116: 1319-29.
3. Igarashi M, Takagi A, Jiang X et al. Analysis of Helicobacter pylori and nonsteroidal anti-inflammatory drug-induced gastric epithelial injury. Aliment. Pharmacol. Ther. 2002; 16 (Suppl. 2): 235-9.
4. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25.
5. Darling RL, Romero JJ, Dial EJ et al. The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 2004; 127: 94-104.
6. Pawlik T, Konturek PC, Konturek JW et al. Impact of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on gastric ulcerogenesis in experimental animals and in humans. Eur. J. Pharmacol. 2002; 449: 1-15.
7. Huang J, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
8. Laine L, Marin-Sorenson M, Weinstein WM. Nonsteroidal anti-inflammatory drug-associated ulcers do not require Helicobacter pylori for their development. Am. J. Gastroenterol. 1992; 87: 1398-402.
9. Moriyama T, Matsumoto T, Fuchigami T et al. Changes in Helicobacter pylori status in patients with rheumatoid arthritis under non-steroidal anti-inflammatory drugs. Scand. J. Gastroenterol. 2004; 39: 111-18.
10. Lai KC, Lau CS, Ip WY et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 2003; 17: 799-805.
11. Hawkey CJ. Personal review: Helicobacter pylori, NSAIDs, and cognitive dissonance. Aliment. Pharmacol. Ther. 1999; 13: 695-702.
12. Mizokami Y, Narushima K, Shiraishi T et al. Non-Helicobacter pylori ulcer disease in rheumatoid arthritis patients receiving long-term NSAID therapy. J. Gastroenterol. 2000; 35 (Suppl. 12): 38-41.
13. Caselli M, Pazzi P, LaCorte R et al. Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 1989; 44: 101-4.
14. Farrow DC, Vaughan TL, Hansten PD et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 97-102.
15. Zaridze D, Borisova E, Maximovitch D et al. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int. J. Cancer 1999; 82: 473-6.
16. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J. Natl Cancer Inst. 2003; 95: 1784-91.
17. Husain SS, Szabo IL, Tamawski AS. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am. J. Gastroenterol. 2002; 97: 542-53.
18. Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and independent mechanisms. Neoplasia 2002; 4: 91-7.
19. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996; 56: 4566-9.
20. Kim TI, Lee YC, Lee KH et al. Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori infected gastric mucosa of mice: apoptosis, cell proliferation and inflammatory activity. Infect. Immun. 2001; 69: 5056-63.
21. Zhu GH, Yang XL, Lai KC et al. Nonsteroidal antiinflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells. Dig. Dis. Sci. 1998; 43: 1957-63.
22. Hahm KB, Song YJ, Oh TY et al. Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible? . J. Biochem. Mol. Biol. 2003; 36: 82-94.
23. Wu AH, Crabtree JE, Bernstein L et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int. J. Cancer 2003; 103: 815-21.
24. Parsonnet J, Samloff IM, Nelson LM et al. Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 1993; 2: 461-6.
25. Jones-Blanket S, Hull MA, Davies GR et al. Non-steroidal anti-inflammatory drugs inhibit Helicobacter pylori-induced human neutrophil reactive oxygen metabolic production in vitro. Aliment. Pharmacol. Ther. 1999; 13: 1653-61.
26. Helena C, Per-Anders M. Antimicrobial activities of N-acetylcysteine and some non-steroidal antiinflammatory drugs. J. Antimicrob. Chemother. 1993; 32: 903-4.
27. Wang WH, Wong WM, Dailidiene D et al. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 2003; 52: 490-5.
28. Lee A, O'Rourke J, De Ungria MC et al. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997; 112: 1386-97.
29. Loeb DS, Talley NJ, Ahlquist DA et al. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology 1992; 102: 1899-905.
30. Sjostrom JE, Kuhler T, Larsson H. Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob. Agents Chemother. 1997; 41: 1797-801.
31. Helena C, Per-Anders M. Antimicrobial activities of non-antibiotic drugs. J. Antimicrob. Chemother. 1993; 32: 355-65.
32. Takahashi S, Fujita T, Yamamoto A. Role of cyclooxygenase -2 in Helicobacter pylori-induced gastritis in Mongolian gerbils. Am. J. Physiol. Gastrointest. Liver Physiol. 2000; 279: G791-8.
33. Gu Q, Xia HHX, Wang WH et al. Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. Aliment. Pharmacol. Ther. 2004; 20: 675-81.
34. Piazza GA, Rahm AK, Finn TS et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997; 57: 2452-9.
35. Piazza GA, Rahm AL, Krutzsch M et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995; 55: 3110-16.
36. Chan TA, Morin PJ, Vogelstein B et al. Mechanisms underlying non-steroidal antiinflammatory drug-mediated apoptosis. Proc. Natl Acad. Sci. USA 1998; 95: 681-6.
37. Soh J-W, Mao Y, Kim M-G et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2 -terminal kinase 1. Clin. Cancer Res. 2000; 6: 4136-41.
38. Kokoska ER, Wolff AB, Deshpande Y et al. Nonsteroidal anti-inflammatory drugs attenuate epidermal growth factor-induced proliferation independent of prostaglandin synthesis inhibition. J. Surg. Res. 1999; 84: 186-92.
39. Ivanov IT, Tzaneva M. Direct cytotoxicity of non-steroidal anti-inflammatory drugs in acidic media: model study on human erythrocytes with DIDS-inhibited anion exchanger. Pharmazie 2002; 57: 848-51.